



RESEARCH ARTICLE

CLINICAL PROFILE AND OUTCOME OF CONJUGATED NEONATAL HYPER BILIRUBINIMIA
IN A TERTIARY PEDIATRIC HOSPITAL

¹Dr. Joydeep Das, ²Dr. Jayita Das and ^{3,*}Dr. Devyani De

¹Associate Professor of Pediatrics, Jagannath Gupta Institute of Medical Science, Budge Budge, Kolkata

²DNB (Pediatrics) Resident at Institute of Child Health, Kolkata

³Assistant Professor, Dept. of Biochemistry, Calcutta National Medical College

ARTICLE INFO

Article History:

Received 29th June, 2018

Received in revised form

25th July, 2018

Accepted 10th August, 2018

Published online 30st September, 2018

Key Words:

Biliary Atresia,

Kasai's Operation,

Congugated, Bilirubin.

ABSTRACT

Introduction: Neonatal cholestasis is a silent emergency (National Biliary Atresia Registry, 1976). In a tertiary care hospital we can diagnose many cases but outcome depends on post natal age, if post natal age crosses 8 weeks of age prognosis is guarded. Very few studies captured clinical profile and outcome which can alert a practicing pediatrician about the nature of severity and long term follow up (Ohkohchi 1989). **Aims and objectives:** Outline the etiology and clinical profile of different cases of Conjugated neonatal hyperbilirubinemia and their outcome over 1 year follow up. **Materials and Method:** Babies with conjugated hyperbilirubinemia more than 20% of total bilirubin presenting at more than 14 days of age at OPD or emergency of Institute of Child Health, Kolkata were admitted in the hospital and started investigation as per standard protocol. Those diagnosed as biliary atresia were referred to pediatric surgery and Kasai's operation was done as early as possible preferably within 8 weeks of life. Those presenting later than 10 to 12 weeks where chance of failed Kasai was very high were put on palliative care after discussion with parents. In this prospective cohort study of 46 patients of conjugated hyperbilirubinemia in a neonate is followed up over 12 months and analysed the morbidity and mortality. **Result and analysis:** Idiopathic neonatal hepatitis 14 (30.5%) was very high followed by biliary atresia BA 11 (24%), sepsis 8 (17.39%) and hypothyroidism 4 (8.69%). Down syndrome and infant of diabetic mother constitute 6.5% (3) each followed by CMV2 (4.3%) and Galactosemia 1 (2.17%). Out of 46 cases 17 cases were died within the follow up period of 8 months. No death is reported within 8 to 12 months. Among 17 cases of death BA were 6, rest 11 were due to medical cause. **Conclusion:** The prognosis for infants with neonatal cholestasis syndrome especially due to biliary atresia remains dismal, particularly in our country. It is unfortunate that 35 years after Morio Kasai's first reported success with his portoenterostomy operation our patients still not benefited from the same. Due to delay in diagnosis most babies undergo surgery late and ultimately need a liver transplant.

Copyright © 2018, Joydeep Das et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citation: Dr. Joydeep Das, Dr. Jayita Das and Dr. Devyani De. 2018. "Clinical profile and outcome of conjugated neonatal hyper bilirubinimia in a tertiary pediatric hospital", *International Journal of Current Research*, 10, (09), 73210-73213.

INTRODUCTION

Failure of normal amount of bile to reach the duodenum is defined as cholestasis. This may be due to pathology anywhere between the hepatocyte and the ampulla of Vater. Sometimes signs and symptoms are so silent in an asymptomatic baby that it remains undiagnosed for a long time. But aggressive necro-inflammation silently destroys the liver and by the time patient is symptomatic, whole liver has reached an irreversible stage. The major difficulty in the management of these babies is that the etiology of cholestasis is multifactorial and the final

outcome in many conditions is determined by the early diagnosis and treatment, while the initial presenting symptoms and signs are usually non specific apart from hepatosplenomegaly, mild jaundice and pale stools. In an otherwise well baby caregiver or parents or treating physician does not pay any attention. Recently joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition recommends that any infant noted to be jaundiced after 2 weeks of age be evaluated for cholestasis and an elevated serum direct bilirubin level (direct bilirubin levels >1.0mg/dL or >17µmol/L) warrants timely consideration for evaluation and referral to a pediatric gastroenterologist or hepatologist (Fawaz et al., 2017). After 4 weeks of life "every day past is one battle lost" specially in cases of untreated metabolic

*Corresponding author: Dr. Devyani De

Assistant Professor of Biochemistry, Calcutta National Medical College

DOI: <https://doi.org/10.24941/ijcr.32167.09.2018>

disease like tyrosinemia, galactosemia where accumulated substances due to deficient enzyme causes hepatocellular inflammation leading to progressive hepatitis, cholangitis and fibrosis. Due to advent of molecular diagnosis a small sub population of idiopathic neonatal hepatitis are nowadays diagnosed as Allagile, Zellweger or Bylar's disease. Very few studies captured clinical profile and outcome which can alert a practicing pediatrician about the nature of severity. In this prospective cohort study of 46 patients of conjugated hyperbilirubinemia in a neonate, is followed up over 12 months and analysed the morbidity and mortality.

MATERIALS AND METHODS


Babies with conjugated bilirubin more than 20% of total bilirubin in presenting after 14 days of life at out patient department (OPD) or emergency of Institute of Child Health from March 2010 to April 2011 were included in the study. All patients were admitted in the pediatric ward or neonatal intensive care unit (NICU) of this hospital and started investigation and management as per standard protocol (Bhatia, 2014).

Hep B, HIV, negative sepsis screen, normal coagulation profile, no clues in metabolic screen were subjected to HIDA scan and liver biopsy with proper consent. Those cases are undisputed biliary atresia on liver biopsy were immediately referred to pediatric surgery for portoenterostomy of Kasai. In cases of doubtful biliary atresia with or without excretion of dye in HIDA scan subjected to laparotomy and peroperative cholangiography. If any conclusion with respect to biliary atresia Kasai's operation was done. If liver biopsy showed hepatitis with partial or complete excretion of dye were followed up as neonatal hepatitis. To diagnose suspected metabolic disease we depend on urinary reducing substance and odour. All positive non glucose reducing substance were subjected to ferric chloride test, and if metabolic disease is suspected sample was sent to referral laboratory for Tandem Mass Spectrometry.

RESULTS AND ANALYSIS

A total of 46 babies were included in this study from March 2010 to April 2011, and followed 12 months prospectively at an interval of two month upto April 2012.

Approach to a Case of Neonatal Cholestasis (Standard Protocol)



According to that all the babies were subjected to complete blood count with malarial parasite, sepsis screen, blood culture, urine routine and culture, blood gas, liver function test, thyroid profile, selective TORCH screen, serology for HIV, hepatitis Band ultrasonography of whole abdomen. Sick babies were treated for sepsis with intravenous fluid, antibiotics, vitamin k and with or without parenteral nutrition. The non sick looking babies with pale stool, negative serology of TORCH,

Out of 46 babies 25 were male and 21 female. Mean age of presentation to hospital with cholestasis was 42 days. All cases of trisomy 21 had maternal age less than 35 yrs and were nondysjunction of 21st chromosome on karyotype. Cardiac defect was universally present and was picked up early, so no case went to heart failure and subsequent rise of bilirubin by passive venous stasis in liver. All the babies were not sick looking and liver enzymes were proportionately raised with visualization of extrahepatic biliary tract on ultrasound of liver.

Table 1. Clinical Profile and outcome

| | | | |
|----|-----------------------------------|----|---|
| 1) | Hypothyroidism | 4 | 3 → Normal growth and development after treatment 1→ Lost in follow up |
| 2) | TORCH Infection(CMV) | 2 | Both died in the hospital |
| 3) | Metabolic disorder(Galactosemia) | -1 | Died→ due to septicemica |
| 4) | Down's Syndrome | 3 | 1 → died after 6 months 1→resolution of jaundice and are growing well with anticongestive medications 1→Resolution of cholestasis. |
| 5) | Sepsis | 8 | 2 →died due to fulminant sepsis 6→ responded to antibiotics |
| 6) | Choledochal cyst | 1 | Operated doing well at 12 month |
| 7) | Infant of Diabetic mothers | 3 | All of them survived and are doing well at12 month follow up. |
| 8) | BiliaryAtresia | 10 | 2→ died after 3 days of admission due to liver failure 6→ Undergone Kasai's operation a)2 → died in post operative period b)3→Mild to Mod. Symptom at 12month. c)1 → No follow up 2 →Did not gave consent for kasai died at 6 month follow up. |
| 9) | IdeopathicNeonatal Hepatitis(INH) | 14 | 3 → died due to liver failure at 3month. 3→ developed cirrhosis at 9months. 3 → Jaundice resolved doing well. 2→Died due to liver failure at 6--8 months 3→ Lost in follow up. |

Table 2. Clinical and Laboratory profile of Down syndrome with cholestasis

| Number of cases | Age at presentation | Karyotype | Age Mother | Cardiac defect | TSH | Bilirubin Total/direct | SGPT | SGOT | Alk. PO4 | γGT |
|-----------------|---------------------|-------------------|------------|----------------|-----|------------------------|------|------|----------|-----|
| Case1 | 32days | 47 XY(Trisomy 21) | 32 | Tiny ASD | 8.6 | 16.2/4.3 | 434 | 233 | 546 | 187 |
| Case2 | 24days | „ | 28 | Small ASD | 5.9 | 21.4/6.7 | 343 | 287 | 654 | 212 |
| Case3 | 36days | „ | 29 | Small VSD | 9.7 | 13.5/3.8 | 256 | 322 | 756 | 267 |

Table 3. Clinal and Laboratory profile of Hypothyroid cases

| Number of cases | Age at presentation | Dry skin | Constipation | TSH | FT4 | FT3 | Bilirubin Tot/Direct | SGPT | SGOT | Alk PO4 | γGT |
|-----------------|---------------------|----------|--------------|------|-----|-----|----------------------|------|------|---------|-----|
| 1 | 23 days | ++ | ++ | 24 | 2.3 | 1.2 | 17.5/7.8 | 138 | 154 | 435 | 112 |
| 2 | 28days | + | ++ | 18 | 1.2 | 0.7 | 13.6/5.6 | 189 | 132 | 443 | 96 |
| 3 | 34days | +++ | ++ | 31.5 | 0.9 | 0.8 | 16.8/6.5 | 123 | 166 | 564 | 134 |

Table 4. Clinical and Lab profile of infant of diabetic mother

| Sl. no | SGA/LGA | Polycythemia PCV<60 | Hypoglycemia | Hypocalcemia | Cong. Anomaly | SGPT | SGOT | Alk PO4 | TSH | Asymmetricseptal Hypertrophy |
|--------|---------|---------------------|--------------|--------------|---------------|------|------|---------|-----|------------------------------|
| 1 | LGA | Hb 20 | ++ | ++ | Nil | 433 | 343 | 432 | <10 | Mild |
| 2 | LGA | HB19.7 | ++ | ++ | Nil | 534 | 445 | 456 | <10 | Moderate |
| 3 | LGA | HB18.75 | ++ | ++ | Nil | 328 | 298 | 387 | <10 | Moderate |

Table 5. Outcome of Kasai operation

| Case number | Age at presentation | Day of operation | Post operative complication Leading to death, n=2 | | 12 month outcome |
|-------------|---------------------|------------------|---|------------------|-------------------|
| | | | Infection | Perforated stoma | |
| 1 | 63days | 73days | +++ | No | Death at 88days |
| 2 | 65days | 76 days | No | +++ | Death at 86days |
| 3 | 37days | 45days | No | No | Asymptomatic |
| 4 | 35days | 42days | No | No | Mod symptom |
| 5 | 33days | 40days | No | No | Minimal symptom |
| 6 | 39days | 47days | No | No | Lost in follow up |

Table 6. Analysis of Symptom at 12 month post Kasai

| Case number | Wt. for age Centile | Length for age. Centile | Portal HTN | Palmer Erythema | Digital Clubbing |
|-------------|---------------------|-------------------------|------------|-----------------|------------------|
| 3 | 50 th | 50 th | Regressed | No | No |
| 4 | 30 th | 30 th | Same at 6m | No | GradeII |
| 5 | 40-50 th | 40-50 th | Same at 6m | Yes | GradeII |

Table 7. Age of death due to different causes of Neonatal Cholestasis

| Cause | Age of death |
|------------------------------------|--------------|
| 1) CMV | 32 days |
| 2) CMV | 59 days |
| 3) Galactosemia | 49 days |
| 4) Down syndrome | 7 months |
| 5) Sepsis | 21 days |
| 6) Sepsis | 29 days |
| 7) BA(Before Kasai, delayed refer) | 80 days |
| 8) BA(Before Kasai, delayed refer) | 93 days |
| 9) BA(Post operativePd) | 63 days |
| 10)BA(Post operativePd) | 65 days |
| 11)BA(No consent for Kasai) | 180days |
| 12)BA(No consent for Kasai) | 172days |
| 13) INH | 90 days |
| 14) INH | 119 days |
| 15) INH | 120 days |
| 16)INH | 240days |
| 17)INH | 210days. |

Case 2 was doing well died at 6 month due to massive pneumonia All the hypothyroid cases presented within three weeks of life with classical signs of dry skin, constipation, lethargy, poor cry, excessive sleepiness and jaundice. TSH was disproportionally high with respect to FT4 and FT3. Liver enzymes were universally raised but after starting Thyroxin to all 3 babies showed good response in clinical features as well as resolution of cholestasis. All the three cases of infant of diabetic mother who presented after 2weeks of life with conjugated hyperbilirubinemia had large body mass as compared to gestational age, needed intravenous glucose and calcium for first seven days of life. On full oral feed these babies were doing well with calcium supplementation and frequent feed. Moderate septal hypertrophy noted in two cases, did well on follow up. Liver enzymes and cholestasis resolved at 6 and 12 month follow up. From the above table it is concluded that survival depends on age of operation, but there may be other determinants in cholestasis free life. In spite of early operation within 6 weeks of life our case number 4 and 5 has some symptoms of cholestasis.

In this very small cohort, in spite of post operative success two cases showed signs of liver failure at 12 months follow up. More follow up data is required to comment on slowly evolving progressive liver disease even if biliary canaliculi is patent initially. All death cases were analysed and their mode of death were due to chronic liver failure complicated with portal hypertension, ascitis, encephalopathy and coagulopathy. Medical management could support the failing liver to some extent but without hepatic replacement therapy there is no hope.

Conclusion

Misdiagnosis of cholestasis as physiologic jaundice delays the identification of severe liver diseases. In the majority of infants, prolonged physiologic jaundice represent benign cases of breast milk jaundice, but few among them are masked and caused by neonatal cholestasis that requires a prompt diagnosis and treatment. Extra hepatic biliary atresia is a surgically correctable anatomical defect which can be operated surgically by an expert pediatric surgeon. But we the practicing pediatrician as well as community physicians lack adequate knowledge and awareness for early detection, early intervention and early surgical referral. In the year 1992, the department of Pediatric surgery of LTMG Hospital, Sion, Mumbai correctly recommended inclusion of "Neonatal jaundice with particular reference to biliary atresia" in all maternal and child health programmes and Launching of a media and poster campaign aimed at patients, health workers and family practitioners to increase the awareness on this issue and stressing the importance of prolonged jaundice in newborn, yellow urine and white stools as signs of a hepatobiliary disorders. All consensus report, case series, case report in the existing literature identified one common variable for the successful treatment of neonatal cholestasis syndrome is "early referral".

REFERENCES

- Bhatia et al. 2014. Management of Neonatal Cholestasis: Consensus Statement of the Pediatric Gastroenterology Chapter of Indian Academy of Pediatrics, P 203-209, volume 51.
- Fawaz R¹, Baumann U., Ekong U. et al., 2017. Guideline for the Evaluation of Cholestatic Jaundice in Infants: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition; *J Pediatr Gastroenterol Nutr.*, Jan;64(1):154-168.
- Lilly JR., Altman RP. 1975. Hepatic portoenterostomy (the Kasai operation) for biliary atresia. *Surgery.* Jul;78(1):76-86
- National Biliary Atresia Registry, 1976. American Academy of Pediatrics. 1976.
- Ohkohchi M., Chiba T., Enop N., Goto M., Ibrahim, M . 1989. Outcome of neonatal jaundice: *J Pediatr Gastroenterology Nutr.*, 9:406-420.
